Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?
Open Access
- 13 May 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Rheumatology Reports
- Vol. 14 (4), 324-333
- https://doi.org/10.1007/s11926-012-0261-7
Abstract
Major scientific advances in basic science, pharmacology, and translational medicine have allowed the discovery of new molecular targets whose manipulation by new chemical entities has led to treatments for inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Development of new agents for systemic lupus erythematosus (SLE) has lagged, however, because the protean manifestations of SLE present challenges for measuring therapeutic effects in a consistent manner. Composite end points combining several Disease Activity Indices (DAIs) are being used in ongoing global studies, but the uniform application of these complex DAIs across large numbers of clinical sites has proven difficult. We describe herein approaches that are being utilized to facilitate collection, review, and analysis of the clinical measures utilizing independent central adjudication committees.Keywords
This publication has 45 references indexed in Scilit:
- Treatment of systemic lupus erythematosus with epratuzumabBritish Journal of Clinical Pharmacology, 2011
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals Of The Rheumatic Diseases, 2010
- Blinded Independent Central Review of the Progression-Free Survival EndpointThe Oncologist, 2010
- Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusArthritis Research & Therapy, 2010
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosusJCI Insight, 2009
- The BILAG-2004 index is sensitive to change for assessment of SLE disease activityRheumatology, 2009
- The Cutaneous Lupus Erythematosus Disease Area and Severity IndexArchives of Dermatology, 2008
- Disease-Modifying Agents for Multiple SclerosisDrugs, 2008
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992